Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Survey to Assess Why People Are Not Responding to Treatment in Hypertension

This study has been completed.
Sponsor:
Collaborator:
International Clinical Trials Association
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT01071681
First received: October 1, 2009
Last updated: November 1, 2011
Last verified: November 2011
History of Changes

October 1, 2009
November 1, 2011
November 2009
September 2010   (final data collection date for primary outcome measure)
Percentage of patients, according to the level of cardiovascular risk, who, at the end of the visit:- do not present any modification of hypertension treatment (therapeutic inertia) - present a change in the hypertension therapeutic [ Time Frame: on day 1 ] [ Designated as safety issue: No ]
Percentage of patients, according to the level of cardiovascular risk, who, at the end of the visit: - do not present any modification of hypertension treatment (therapeutic inertia) - present a change in the hypertension therapeutic [ Time Frame: on day 1 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01071681 on ClinicalTrials.gov Archive Site
Analyses of the factors that had an impact on the therapeutic decision [ Time Frame: on day 1 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
Observational Survey Assessing the Factors of Treatment Intensification in Uncontrolled Hypertensive Patients Under a Combination Therapy, Either Fixed or Not, of a Renin-Angiotensin System Blocker (RASB) and Hydrochlorothiazide (HCTZ), According to Their Level of Cardiovascular Risk.

This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   None Retained
Description:

n.a
Non-Probability Sample

Uncontrolled hypertensive patients under a combination therapy, either fixed or not, of a renin-angiotensin system blocker and hydrochlorothiazide
Arterial Hypertension
Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
Patients under daily life treatment receiving Pritor according to local drug information.
Group 1
Intervention: Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1589
September 2010
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men or women over 18
  • Hypertensive patients
  • Uncontrolled hypertension (blood pressure >/=140/90 mmHg on the day of consultation or >/=130/80 mmHg in diabetic patients or in patients suffering from kidney failure, or in elderly patients with a systolic blood pressure >/=150 mmHg (in the absence of orthostatic hypotension)
  • Patients treated with a combination, fixed or not, of Renin-Angiotensin System Blocker (RASB) + Hydrochlorothiazide (HCTZ)
  • Patients examined in common medical care practice, whatever the reason for consultation
  • Patients informed of the study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01071681
14675, KL0911FR, BI INTENS
No
Medical Director, Bayer Schering Pharma AG
Bayer
International Clinical Trials Association
Study Director: Bayer Study Director Bayer
Bayer
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP